Dimethyl Sulfoxide
Apexbio Technology LLC EPZ-6438 1403254-99-8 10mM (in 1mL DMSO)
EPZ-6438 is a selective inhibitor targeting EZH2 the catalytic subunit of polycomb repressive complex 2 (PRC2) By competitively binding to EZH2 s S-adenosylmethionine (SAM) pocket EPZ-6438 suppresses EZH2-driven trimethylation of histone H3 lysine 27 (H3K27me3) a key epigenetic modification implicated in transcriptional regulation and oncogenesis This selective inhibition of EZH2 exhibits reduced affinity for EZH1 In biological studies EPZ-6438 has demonstrated anti-tumor activity in preclinical malignant rhabdoid tumor models making it useful for examining EZH2-dependent cancer pathways and epigenetic research
Apexbio Technology LLC Pomalidomide (CC-4047) 19171-19-8 10mM (in 1mL DMSO)
Pomalidomide (CC-4047) an immunomodulatory derivative structurally related to Thalidomide exhibits anti-tumor and anti-angiogenic properties Chemically the molecule is distinguished by additional amino substituent at the fourth position of the phthalimide ring and two extra oxy groups Its mechanism of action includes modulation of specific cytokines within the tumor microenvironment (TNF- IL-6 IL-8 VEGF) suppression of tumor cell proliferation and modification of host immune cell activity Pomalidomide is widely studied in biomedical research particularly in therapeutic exploration for hematologic malignancies such as multiple myeloma including relapsed or refractory disease states
Apexbio Technology LLC GW0742 317318-84-6 10mM (in 1mL DMSO)
GW0742 is a synthetic selective agonist of peroxisome proliferator-activated receptor / (PPAR / ) a ligand-dependent transcription factor involved in regulating lipid metabolism inflammation and energy homeostasis Activation of PPAR / modulates downstream gene transcription influencing physiological processes including inflammatory responses and neuronal protection Experimental studies demonstrate GW0742 s role in attenuating inflammation-mediated tissue injury such as ischemia/reperfusion-induced intestinal damage as well as mitigating radiation-induced neuroinflammation and cognitive impairment in animal models Thus GW0742 serves as a research tool to study PPAR / specific pathways in inflammatory diseases metabolic processes and neuroprotective mechanisms
Apexbio Technology LLC Gemfibrozil 25812-30-0 10mM (in 1mL DMSO)
Gemfibrozil is a small-molecule pharmacological agent that functions primarily through activation of the nuclear receptor peroxisome proliferator-activated receptor-alpha (PPAR ) By modulating PPAR signaling pathways gemfibrozil regulates lipid metabolism influencing the transcription of genes associated with fatty acid oxidation and lipoprotein synthesis resulting in reduced triglyceride levels and altered lipoprotein profiles In biomedical research contexts gemfibrozil is utilized to explore molecular mechanisms underlying lipid metabolic processes atherosclerosis progression and related metabolic disorders Furthermore gemfibrozil serves as a useful experimental tool to dissect PPAR -dependent pathways and to investigate therapeutic potentials targeting lipid abnormalities and cardiovascular disease
Apexbio Technology LLC Cyclosporin A 59865-13-3 10mM (in 1mL DMSO)
Cyclosporin A is an immunosuppressive agent acting primarily through inhibition of cyclophilins intracellular peptidyl-prolyl isomerases with a reported IC50 of 7 nM Cyclophilins regulate mitochondrial permeability transition pore (MPTP) opening intracellular calcium signaling and NFAT transcriptional activation pathways Cyclosporin A s ability to inhibit calcineurin-NFAT signaling in T-cell activation leads to suppression of inflammatory immune responses indicating potential use in autoimmune disorder research Additionally it modulates cell apoptosis and survival mechanisms in diverse models including retinal ischemic injury viral entry (HBV HCV) and tumor biology in colon cancer cell lines
Apexbio Technology LLC Romidepsin (FK228, depsipeptide) 128517-07-7 10mM (in 1mL DMSO)
Romidepsin (FK228 depsipeptide CAS 128517-07-7) is a small-molecule inhibitor targeting histone deacetylases (HDACs) Initially isolated from Chromobacterium violaceum romidepsin preferentially inhibits class I enzymes HDAC1 and HDAC2 over class II HDAC4 and HDAC6 Inhibition of HDAC activity by romidepsin results in increased histone acetylation promoting transcriptional activation of tumor suppressor genes Mechanistically this compound can trigger cellular differentiation cell-cycle arrest apoptosis and altered gene expression in various malignancies Romidepsin serves as a research tool to investigate epigenetic regulation and has notable anticancer properties in cell models such as neuroblastoma and cutaneous T-cell lymphoma
Medchemexpress LLC Puromycin 10 Mm 1 Ml In Dmso | HY-B1743-10 MM 1 ML IN
Puromycin 10 Mm 1 Ml In Dmso
Sigma Aldrich Fine Chemicals Biosciences CryoSOfreeTM DMSO free Cry
We are committed to bringing you Greener Alternative Products which adhere to one or more of The 12 Principles of Greener Chemistry. This product has Inherently Safer Chemistry compared to the standard use of DMSO for cryopreservation of cell cultures. for more information see here.
Apexbio Technology LLC Efavirenz 154598-52-4 10mM (in 1mL DMSO)
Efavirenz is a non-nucleoside reverse transcriptase inhibitor targeting human immunodeficiency virus type-1 (HIV-1) reverse transcriptase (RT) It functions by binding specifically to an allosteric site of HIV-1 RT thereby inhibiting viral RNA-dependent DNA polymerase activity essential for HIV replication Efavirenz exhibits inhibitory activity against wild-type HIV-1 RT with reported IC95 values ranging from approximately 1 5 to 3 nM and retains inhibitory potency against several known NNRTI-resistant RT variants Due to its molecular mechanism and specificity Efavirenz is frequently utilized in antiviral studies particularly HIV research investigating RT inhibition and HIV resistance mechanisms
Apexbio Technology LLC LY2228820 862507-23-1 10mM (in 1mL DMSO)
LY2228820 (CAS 862507-23-1) is a potent selective ATP-competitive small-molecule inhibitor targeting the and isoforms of p38 mitogen-activated protein kinase (MAPK) with reported IC50 values of 5 3 nM and 3 2 nM respectively By suppressing p38 MAPK signaling LY2228820 decreases phosphorylation of heat shock protein 27 (HSP27) induced by Bortezomib thereby elevating cytotoxic effects in multiple myeloma (MM) models Additionally it inhibits secretion of IL-6 by bone marrow mononuclear cells and stromal cells as well as secretion of MIP-1 by patient-derived MM cell subsets and osteoclast precursors In melanoma (B16-F10) and NSCLC (A549) xenograft murine models LY2228820 reduces phosphorylation of MK2 and slows tumor progression respectively highlighting its potential utility in oncology research
Apexbio Technology LLC Levosimendan 141505-33-1 10mM (in 1mL DMSO)
Levosimendan (CAS 141505-33-1) is a small molecule calcium sensitizer that exerts its pharmacological action by binding selectively and in a calcium-dependent manner to cardiac troponin C (cTnC) Through this interaction levosimendan facilitates cardiac muscle contraction without significantly increasing intracellular calcium concentrations Research indicates utility in heart failure treatment where improved myocardial contractility is therapeutically desirable Currently levosimendan is evaluated extensively in Phase 4 clinical studies to explore its efficacy and therapeutic profile
Apexbio Technology LLC Danusertib (PHA-739358) 827318-97-8 10mM (in 1mL DMSO)
Danusertib (PHA-739358 CAS 827318-97-8) is a pyrrolopyrazole-based aminopyrazole derivative that functions as a pan-inhibitor of aurora kinases prominently targeting aurora B kinase (ABK) It also exhibits inhibitory activity against several other tyrosine kinases including the T315I mutant form RET TRK-A and fibroblast growth factor receptor-1 (FGFR-1) Due to its broad kinase inhibition profile danusertib has demonstrated significant antitumor activity in various xenograft spontaneous and genetically engineered animal models and is thus useful in oncology research involving leukemia and solid tumors
Apexbio Technology LLC SU11274 658084-23-2 10mM (in 1mL DMSO)
SU11274 (CAS 658084-23-2) is a selective inhibitor targeting Met kinase exhibiting an IC50 of approximately 10 nM The compound specifically suppresses the autophosphorylation of Met at residues Tyr1234/1235 disrupting receptor activity with minimal effects on other receptor tyrosine kinases such as EGFR and PDGFR or serine/threonine kinases including CDK2 In NIH3T3 cells expressing drug-sensitive or resistant MET mutants and in H1993 human lung cancer cells treatment with SU11274 induces a dose-dependent inhibition of Met phosphorylation and impairs receptor ubiquitination leading to receptor accumulation SU11274 serves as a useful tool for investigating Met signaling pathways in oncology research
Sigma Aldrich Fine Chemicals Biosciences Dimethyl sulfoxide | 67-68-5 | MFCD00002089 | 4 x 2 mL
Dimethyl sulfoxide | Purity: ≥99.9% | Mol Wt: 78.13 | 67-68-5 | MFCD00002089 | 4 x 2 mL
Sigma Aldrich Fine Chemicals Biosciences Dimethyl sulfoxide suitable for HPLC, >=99.7% | 67-68-5 | MFCD00002089 | 4X2L
Dimethyl sulfoxide suitable for HPLC, >=99.7% | Purity: >=99.7% | Mol Wt: 78.13 | 67-68-5 | MFCD00002089 | 4X2L